The role of positive lymph node location in nonesmall-cell lung cancer (NSCLC) patients and effects on survival was assessed. A total of 88 operated patients with unsuspected N2 disease or station 10 lymph nodes were included. No difference was found in survival between inferior positive mediastinal N2 node patients compared to multilevel N2 disease patients. The survival of patients with positive hilar disease was similar to the inferior mediastinal positive N2 group. Background: The role of surgery in the treatment of nonesmall-cell lung cancer that has spread to ipsilateral mediastinal or hilar lymph nodes (LNs) is controversial. We examined whether the location of LNs positive for nonesmall-cell lung cancer in mediastinum or hilum influences the survival of these patients. Patients and Methods: We reviewed data from 881 patients and analyzed those with unsuspected N2 disease or hilar (station 10) LNs. The patients were stratified into the following groups: group A, positive hilar Naruke 10; group B, superior mediastinal and aortic nodes (Naruke 1, 2, 3, 4, 5, and 6); group C, inferior mediastinal nodes (Naruke 7, 8, and 9), and multilevel group D (2 or more positive N2 levels). Results: A total of 69 pN2 and 19 pN1 patients were included. Progression-free survival (PFS) was statistically significant better in group B versus group C (P ¼ .044) and group B versus group D (P ¼ .0086). The overall survival (OS) of group A did not differ from that of group C. A statistically significant better OS was found between groups B and D (P ¼ .051). Conclusion: Inferior positive mediastinal N2 node patients seem to have an OS and PFS as poor as multilevel N2 disease patients. The OS and PFS of patients with positive hilar disease are similar to those in the inferior mediastinal positive N2 group. Superior positive mediastinal N2 node patients have better OS and PFS than the inferior mediastinal positive N2 group.
Introduction
According to the Finnish Cancer Registry, lung cancer is the leading cause of cancer-related deaths in men (21.6%) and the second most common cause in women (13.5%). 1 The optimal treatment and prognosis of lung cancer depends on disease stage.
The role of surgery in patients with stage IIIA disease is controversial, especially in mediastinal N2 disease. 2 Despite systemic induction chemotherapy, 3, 4 patients with mediastinal lymph node (LN) involvement have a poor prognosis. The correlation of prognosis to location and extent of mediastinal LN involvement is unclear. [5] [6] [7] [8] Recently it has been shown that single-level N2 disease survival differs from that of multilevel N2 disease. 9 There are also reports on patients with lower mediastinal metastasis that indicate a significantly better prognosis than those with upper mediastinal metastasis. 10 To further clarify this matter, we retrospectively analyzed a patient series to understand the correlation between the extent of mediastinal disease involvement and the given location of the involvement to progression-free survival (PFS) and overall survival (OS).
Patients and Methods

Patients
Between January 2004 and December 2014, a total of 881 patients underwent anatomic R0 lung resection with mediastinal lymphadenectomy for primary lung cancer at Helsinki University Hospital. All patients were preoperatively evaluated by a multidisciplinary lung tumor board for primary operative management. The study group consisted of patients who were clinically staged as having N0 disease. We excluded patients with clinically suspected N1 or N2 disease on imaging or confirmed before resection. Of these, we excluded 34 patients who had intraparenchymal positive LNs limited to stations 11 or 12 or both. The type of surgery performed was lobectomy, sleeve, or bilobectomy ( Table 1) .
Methods
For staging, we used the 7th edition of the tumor, node, metastasis classification system. We defined unsuspected N2 disease as final pathologic N2 disease without suspected mediastinal LN involvement in preoperative examinations. Every patient was staged by computed tomography (CT). Fifty-four patients (61.4%) were staged with positron emission tomography (PET)-CT, and selective mediastinoscopy was performed on 3 patients (3.4%). Both mediastinoscopy and PET-CT were performed on 2 patients (2.3%). Preoperative evaluations included a spirometry test and measurements of pulmonary diffusing capacity for carbon monoxide using the single-breath method. The Naruke LN map was used for classification. 11 In this classification system, station 10 LNs were regarded as N1 nodes (hilar, main bronchus nodes). The sites of N2 LNs were grouped as follows: superior mediastinal (station 1, highest mediastinal nodes; station 2, upper paratracheal nodes; station 3, prevascular and retrotracheal; station 4, lower paratracheal nodes; station 5, subaortic nodes; and station 6, para-aortic nodes) and inferior mediastinal (station 7, subcarinal nodes; station 8, paraesophageal nodes; and station 9, pulmonary ligament nodes) LNs. We excluded 9 pneumonectomy patients from our analysis because of inherent increased morbidity and mortality in the followup of this subpopulation. The patient flowchart is shown in Figure 1 , and preoperative data are listed in Table 2 .
LN Subclassification
We classified our patients into the following 4 groups: group A consisted of pN1 with positive hilar Naruke 10 (n ¼ 19), group B consisted of pN2 patients with superior mediastinal and aortic positive nodes (Naruke 1, 2, 3, 4, 5, and 6 levels, n ¼ 20), group C consisted of pN2 patients with inferior mediastinal positive nodes (Naruke 7, 8 , and 9 levels, n ¼ 24), and group D consisted of multilevel pN2 (2 or more positive N2 levels, n ¼ 25).
Statistical Analysis
Statistical analysis was performed by SPSS 22.0 (IBM SPSS, Chicago, IL). Results are reported as the median (range). Normality was tested by the Shapiro-Wilk test. The Student t test was used to compare scalar values for groups with normal distributions. The Mann-Whitney U test was used for nonnormal scalar analysis. Comparisons of PFS and OS were performed using Kaplan-Meier analysis and the log-rank test. P < .05 was considered statistically significant. Consent was granted for the study by the hospital scientific review board.
Results
A total of 88 patients met the inclusion criteria for this study. We included 19 hilar pN1 and 69 pN2 patients in our final analysis ( Figure 1 ). Tumor characteristics are presented in Table 2 . The incidence of unsuspected pN2 disease was 7.8% in our study. Fortyeight patients (54.5%) received adjuvant chemotherapy; none received postoperative radiotherapy. Thirty-day mortality was 2.3% (2 patients). Causes of death were stroke (1 patient) and acute respiratory distress syndrome (1 patient). The operative morbidity was 27.3%; the most common morbidity was pneumonia. Tumors were localized in upper lobe (n ¼ 42, 47.7%), middle lobe (n ¼ 6, 6.8%), and lower lobe (n ¼ 40, 45.5%). Groups B and D had the most upper-lobe tumors (n ¼ 12 vs. n ¼ 14, 60% vs. 56%, respectively). Tumor in lower-lobe was most common in group C (n ¼ 16, 66.7%). The median PFS was 24 months (range, 0-133 months). The 5-year PFS rates were 21.1% (group A), 30% (group B), 12.5% (group C), and 12% (group D). No statistically significant difference in PFS was observed between groups A and B (P ¼ .170), A and C (P ¼ .625), A and D (P ¼ .420), or C and D (P ¼ .735). PFS was statistically significant better in group B versus group C (P ¼ .044) ( Figure 2 ) and group B versus group D (P ¼ .0086) ( Figure 3) ; the Kaplan-Meier survival plot overlapped for groups C and D.
Median OS and 5-year OS for the whole group were 34.5 months (range, 0-134 months) and 23.9%, respectively. The median OS values were 39 months (group A), 51 months (group B), 33 months (group C), and 22 months (group D). The 5-year OS rates were 21% (group A), 35% (group B), 16.7% (group C), and 24% (group D). A statistically significant better OS was found between groups B and D (P ¼ .051) (Figure 4 ). There was no statistically significant difference in OS between groups A and B (P ¼ .143), A and C (P ¼ .846) or groups C and D (P ¼ .82); the Kaplan-Meier survival plot overlapped for groups C and D (Figures 5 and 6 ).
A multivariate Cox regression analysis was performed between groups A, B, C, and D (Table 3) . Age and Charlson comorbidity index were covariants affecting the OS; that is, older patients had better OS than young patients. No other covariates reached significance (sex, forced expiratory volume in 1 second, thoracotomy vs. video-assisted thoracoscopic surgery, preoperative stage) ( Table 3) .
Discussion
Accurate assessment of LN involvement is crucial for treatment and prognosis of NSCLC. Variability in identifying LN stations can lead to their ambiguous staging. Previous studies have shown that involvement of station 10 significantly worsens prognosis compared to other N1 diseases and is similar to that of N2 disease. 10, 12, 13 We sought to determine the correlation between the extent of mediastinal disease involvement and the given location of involvement to PFS and OS. We use the Naruke map at our institution, and we consider those LNs located around the main bronchus as number 10 (N1).
11
The International Association for the Study of Lung Cancer map defines the whole subcarinal LN as level 7, which in the Naruke map corresponds to both level 7 and 10 LNs. In the American Joint Committee on Cancer and the Mountain map, station 10 (N1 nodes) is located distally to the mediastinal pleural reflection. Unsuspected N2-Positive NSCLC Our study group consisted of patients with clinical IA to IIB disease. The unsuspected N2 involvement of 7.8% is in agreement with those of previous studies showing that about 10% of patients with clinical N0 NSCLC were confirmed as having pathologic N2 disease after lobectomy.
14-17
Our results did not show a statistically significant difference in long-term OS between single-station pN2 and station 10 metastasis. This result was also observed between pN1 and pN2 patients with superior mediastinal and positive aortic nodes. Our findings are consistent with Rea et al, 12 who reported similar 5-year survival rates in patients with pN1 and those with singlestation N2 (31% and 18%, respectively). Asamura et al 18 also
reported similar results with 5-year survival rates (54% for pN1 and 48% for pN2). We believe that this reflects the similarity of pN1 and single-level pN2 disease in superior mediastinal and aortic LN metastasis. 
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Clinical Lung Cancer September 2018 -423 aortic pulmonary window. 18 Consistent with the results of Asamura et al, the affected lobe was also most commonly the upper lobe in our study in patients with superior mediastinal LN metastasis. 17 With inferior mediastinal LN metastasis, tumors were more likely in the lower lobe (60%) than in the upper lobe, which is consistent with the findings of Asamura et al. In our study, while group D (multilevel) tumors were more commonly found in the upper lobe than in the lower lobe, the difference was not statistically significant. In our study, we found better OS among older patients. This might be because patients were older in group B (single level N2 superior), who had better OS than group C (single level N2 inferior) or multilevel N2 patients.
In the present study, we observed statistically significantly better PFS in superior N2 patients than in inferior N2 patients. We found a trend for better OS between inferior N2 versus superior N2 even though this was not statistically significant. We did not observe any statistically significant difference in PFS or OS between inferior N2 versus multilevel N2 or by comparing pN1 (station 10) to superior or inferior pN2 single-station LN metastasis. Although there are reports that suggest that subcarinal lymphadenectomy is not always necessary for tumors in the upper lobes, 18 we suggest that for LN sampling, station 7 is relevant for patient outcome irrespective of the location of the primary tumor. Our main finding was that inferior positive mediastinal N2 node patients seem to have as unfavorable OS and PFS as multilevel N2 disease patients, and significantly worse prognosis than superior mediastinal node patients. We also noted that patients with positive hilar disease did not have different PFS than patients with inferior mediastinal positive N2 disease. Both the location of mediastinal LN metastasis and the extent of disease are significant factors in the overall prognosis of NSCLC after surgery. Our study has several limitations. The most significant limitation is the retrospective study design, even with a prospective patient registry. A prospective study would be challenging because of the time required to collect study material, even in a multicenter setting. We also do not have accurate knowledge regarding the quantity of total LNs in all patients; as with video-assisted thoracoscopic surgery, removal of LNs can be performed in a piecemeal fashion. Our sample size was relatively small but was comparable to previous studies in unsuspected N2 disease. [14] [15] [16] [17] Therefore, a risk for type II error exists. We are a specialized high-volume center and perform careful LN sampling of all NSCLC patients. There was no collective reevaluation for micrometastasis in LNs, as this evaluation would be easily biased because of the retrospective nature of the study, and because the quality of reevaluation for N0 and N1 (stations 11 and 12) would not yield a significant new patient cohort for our study.
Conclusion
The current tumor, node, metastasis classification system in lung cancer only assesses the localization of LN stations for LN examination. It seems, however, that the localization of positive LN stations alone is not sufficient for a reliable estimation of survival. In particular, the number of LN stations involved not only affects survival but also affects the anatomic location of the single-level LN metastasis. We observed statistically significant worse survival in multilevel N2 patients than in single-station N2 patients. Inferior positive mediastinal N2 node patients seem to have OS and PFS as poor as multilevel N2 disease patients.
Clinical Practice Points
Involvement of station 10 significantly worsens prognosis compared to other N1 diseases and is similar to that of N2 disease. Unsuspected mediastinal LN metastasis is found in approximately 10% of patient who have surgery for NSCLC. We found that inferior positive mediastinal N2 node patients seem to have as unfavorable OS and PFS as multilevel N2 disease patients and significantly worse prognosis than upper mediastinal node patients. We also noted that patients with positive hilar disease did not have different PFS than patients with inferior mediastinal positive N2 disease. We suggest that during lobectomy stations 10 and 7 should be dissected. 
